creating a new cancer therapy

Theryte's new approach targets the processes that normally stabilise the cancer cell, allowing the creation of novel, first-in-class anti-cancer drugs with a unique mechanism of action and efficacy against difficult-to-treat tumours.

Theryte aims to exploit its intellectual property to:

• Develop the breakthrough technology to select pre-clinical candidates for partnering and licensing
• Advance a new family of anticancer targets for further drug development
• Develop biomarkers to predict treatment response